Omeprazole blocks the action of H+,K+-ATPase in the gastric mucosa and thus inhibits the secretion of hydrochloric acid. We conducted a double-blind multicenter study (45 centers in 13 countries) of 602 patients with benign gastric or prepyloric ulcers to compare the effectiveness of omeprazole (20 mg once daily, 203 patients, or 40 mg once daily, 194 patients) and ranitidine, an H2-receptor antagonist (150 mg twice daily, 205 patients) in promoting ulcer healing and to evaluate the pattern of ulcer relapse during a six-month follow-up. Healing occurred at four weeks in 80 percent of the patients receiving 40 mg of omeprazole, 69 percent of those receiving 20 mg of omeprazole, 69 percent of those receiving ranitidine. At eight weeks, the corresponding figures were 96, 89, and 85 percent. A multivariate analysis of ulcer healing showed that at four weeks the ulcers of significantly more patients receiving omeprazole had healed as compared with patients receiving ranitidine (omeprazole, 40 mg, vs. ranitidine, P less than 0.0005; omeprazole, 20 mg, vs. ranitidine, P = 0.01). At eight weeks, the 40-mg dose of omeprazole was significantly more effective than ranitidine (P = 0.001) or the 20-mg dose of omeprazole (P = 0.03). Ulcer symptoms were relieved faster with omeprazole. In 68 patients receiving concurrent nonsteroidal antiinflammatory drugs, the healing rates at four weeks were 81 percent in the group receiving 40 mg of omeprazole, 61 percent in the group receiving 20 mg, and 32 percent in the group receiving ranitidine; at eight weeks, the corresponding figures were 95, 82, and 53 percent. During the six-month follow-up period (without treatment), significantly more patients in the omeprazole groups were free of symptoms and ulcers than in the ranitidine group. We conclude that in the dose used, omeprazole is superior to ranitidine in the treatment of benign gastric ulcers.
Source Information
AB Hassle, Gastrointestinal Research, Department of Clinical Pharmacology and Medicine, Molndal, Sweden.
This article has been cited by other articles:
Steen, K S S, Lems, W F, Aertsen, J, Bezemer, D, Dijkmans, B A C
(2001). Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. Ann Rheum Dis
60: 443-447
[Abstract][Full Text]
Russell, R I
(2001). Non-steroidal anti-inflammatory drugs and gastrointestinal damage{---}problems and solutions. Postgrad. Med. J.
77: 82-88
[Full Text]
Agrawal, N. M., Campbell, D. R., Safdi, M. A., Lukasik, N. L., Huang, B., Haber, M. M., for the NSAID-Associated Gastric Ulcer Study Group,
(2000). Superiority of Lansoprazole vs Ranitidine in Healing Nonsteroidal Anti-inflammatory Drug-Associated Gastric Ulcers: Results of a Double-blind, Randomized, Multicenter Study. Arch Intern Med
160: 1455-1461
[Abstract][Full Text]
Wolfe, M. M., Lichtenstein, D. R., Singh, G.
(1999). Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs. NEJM
340: 1888-1899
[Full Text]
LANGMAN, M J S
(1998). Omeprazole in the treatment of ulcers induced by NSAIDs • Commentary. Gut
43: 744-746
[Full Text]
Yeomans, N. D., Tulassay, Z., Juhasz, L., Racz, I., Howard, J. M., van Rensburg, C. J., Swannell, A. J., Hawkey, C. J., The Acid Suppression Trial: Ranitidine versus Omep,
(1998). A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. NEJM
338: 719-726
[Abstract][Full Text]
Hawkey, C. J., Karrasch, J. A., Szczepanski, L., Walker, D. G., Barkun, A., Swannell, A. J., Yeomans, N. D., The Omeprazole versus Misoprostol for NSAID-Induce,
(1998). Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. NEJM
338: 727-734
[Abstract][Full Text]
Roth, S. H.
(1996). NSAID Gastropathy: A New Understanding. Arch Intern Med
156: 1623-1628
[Abstract]
Soll, A. H., Practice Parameters Committee of the American Coll, , Achord, J. L., Bozymski, G., Brooks, S., Lanza, F., Lyon, D., Meyer, G., Reinus, J., Schuster, M., Achord, J., Ofman, J., Glassman, P., Laine, L., Tytgat, G., Walsh, J. H., Graham, D. Y., Peterson, W. L.
(1996). Medical Treatment of Peptic Ulcer Disease: Practice Guidelines. JAMA
275: 622-629
[Abstract]
(1994). Rational use of NSAIDs for musculoskeletal disorders. DTB
32: 91-95
[Abstract][Full Text]
Roth, S. H., Tindall, E. A., Jain, A. K., McMahon, F. G., April, P. A., Bockow, B. I., Cohen, S. B., Fleischmann, R. M.
(1993). A Controlled Study Comparing the Effects of Nabumetone, Ibuprofen, and Ibuprofen Plus Misoprostol on the Upper Gastrointestinal Tract Mucosa. Arch Intern Med
153: 2565-2571
[Abstract]
Fennerty, M. B.
(1993). Nonsteroidal Anti-inflammatory Drugs, Ulcers, and Histamine2 Blockers: The Ostrich Phenomenon!. Arch Intern Med
153: 2411-2412
[Abstract]
Cryer, B., Feldman, M.
(1992). Effects of Nonsteroidal Anti-inflammatory Drugs on Endogenous Gastrointestinal Prostaglandins and Therapeutic Strategies for Prevention and Treatment of Nonsteroidal Anti-inflammatory Drug--Induced Damage. Arch Intern Med
152: 1145-1155
[Abstract]
Hixson, L. J, Kelley, C. L., Jones, W. N., Tuohy, C. D.
(1992). Current Trends in the Pharmacotherapy for Peptic Ulcer Disease. Arch Intern Med
152: 726-732
[Abstract]
Soll, A. H., Weinstein, W. M., Kurata, J., McCarthy, D.
(1991). Nonsteroidal Anti-inflammatory Drugs and Peptic Ulcer Disease. ANN INTERN MED
114: 307-319
[Abstract]
(1989). OMEPRAZOLE: A NEW AND POWERFUL ANTI-ULCER DRUG. JWatch General
1989: 1-1
[Full Text]
